摘要
卵巢癌是死亡率最高的妇科恶性肿瘤。缺乏早期诊断方法、治疗棘手和复发率高是目前影响预后最突出的问题,在遵循治疗指南的同时,强调规范化治疗,用规范自觉约束医疗行为,兼顾个体化治疗原则,并对卵巢癌患者实施全程管理。聚腺苷二磷酸核糖聚合酶(PARP)抑制剂作为维持治疗改变了卵巢癌的传统治疗模式。必须高度重视卵巢癌的规范化治疗和全程管理,才能提高其生存率与生活质量。
Ovarian cancer is the most fatal gynecological malignancy.High recurrence rate and lack of early diagnosis and effective treatment methods are currently prominent problems affecting prognosis.While following treatment guidelines,we should emphasize standardized treatments,willingly regulate medical behaviors,take into account princi-ples of individualized treatments,and implement whole-course management for patients with ovarian cancer.The use of poly(ADP-ribose)polymerase inhibitors,as a maintenance therapy,has changed the traditional treatment model of ovarian canc-er.Close attention should be paid to standardized treatments and whole-course management for ovarian cancer patients in or-der to improve their survival and quality of life.
作者
张国楠
Zhang Guonan(Gynecologic Oncology Center,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medi-cine,University of Electronic Science and Technology of China,Chengdu 610041,Sichuan,China)
出处
《肿瘤预防与治疗》
2020年第5期377-382,共6页
Journal of Cancer Control And Treatment
基金
四川省科技厅重点研发项目(编号:2019Y FS0036)。
关键词
卵巢癌
肿瘤细胞减灭术
化疗
全程管理
Ovarian neoplasm
Cytoreductive surgery
Chemotherapy
Whole-course management
